

# Equitable Access to Liver Transplant: Bridging the Gaps in the Social Determinants of Health

Russell Rosenblatt <sup>1</sup>, Hannah Lee,<sup>2</sup> AnnMarie Liapakis <sup>3</sup>, Keri E. Lunsford,<sup>4,5</sup> Andrew Scott,<sup>6</sup> Pratima Sharma <sup>7</sup>, and Julius Wilder<sup>8,9</sup>

The COVID-19 pandemic and social justice movement have highlighted the impact of social determinants of health (SDOH) and structural racism in the United States on both access to care and patient outcomes. With the evaluation for liver transplantation being a highly subjective process, there are multiple ways for SDOH to place vulnerable patients at a disadvantage. This policy corner focuses on three different methods to reverse the deleterious effects of SDOH—identify and reduce implicit bias, expand and optimize telemedicine, and improve community outreach. (HEPATOLOGY 2021;74:2808-2812).

The COVID-19 pandemic and social justice movement have highlighted the impact of social determinants of health (SDOH) and structural racism in the United States on both access to care and patient outcomes.<sup>(1)</sup> SDOH, as defined by the U.S. Department of Health and Human Services, are “conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks.”<sup>(2)</sup> Contextualizing SDOH, along with acknowledging the existence of structural racism and its impact on how inequitable systems and processes foster racial discrimination, is a vital first step in creating interventions to address them.

In the context of liver transplantation (LT), there remain ongoing health inequities among certain vulnerable populations, including typically underserved patients of minority race, ethnicity, and low socioeconomic status (SES). Inequities can also extend to

include sex, geographical, and educational groups that in turn influence access, utilization, and quality of care. Unfortunately, the most vulnerable populations are also those at the highest risk for progression to cirrhosis, thus compounding inherent inequities in access to transplant.

Evaluation for organ transplantation, a life-saving procedure, involves a multistep, highly selective process. Initially, referrals to appropriate subspecialists and a transplant center are required. During evaluation, candidates undergo formal assessment of adequate social support, psychological health, health insurance, adherence, and understanding of treatments. Each step in the transplant evaluation process is an opportunity for inequity to insert itself, resulting in disparate access to listing for transplantation. This manifests through mechanisms related to poor health literacy, lack of insurance or high copay, poor social support, and geographical location. Culture incapacity by health providers and implicit bias at the provider level and health care system level can create additional barriers. Examples of health inequities

*Abbreviations: LT, liver transplantation; SDOH, social determinants of health; SES, socioeconomic status.*

*Received May 20, 2021; accepted May 20, 2021.*

*© 2021 by the American Association for the Study of Liver Diseases.*

*View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).*

*DOI 10.1002/hep.31986*

*Potential conflict of interest: Dr. Liapakis advises for Gilead and received grants from Merck. The AASLD Public Policy Corner is a regular publication of the AASLD Public Policy Committee highlighting key subject areas of AASLD's public policy agenda. The Public Policy Committee advocates for AASLD members and their patients in front of key decision makers including legislators, regulatory agencies and key opinion leaders within the United States Government.*

include lower referral rate for LT and inferior outcomes among Black and Latinx compared to White patients,<sup>(3)</sup> while, in addition to race/ethnicity, sex and health literacy<sup>(4)</sup> also strongly correlate with the likelihood of listing. SES affects both waitlist mortality and post-LT survival as well.<sup>(3)</sup>

To address existing disparities and inequities related to SDOH and structural racism, the American Association for the Study of Liver Diseases (AASLD) has promoted several initiatives: (1) creation of the Diversity committee, which sponsors workshops to reduce the impact of SDOH on liver-related outcomes; (2) engagement and outreach in local communities and organizations to strengthen relationships with patients and patient advocates; (3) public policy advocacy with national government organizations to support equitable access for liver disease treatment, financial coverage for LT, and funding for health care disparities research; and (4) formal declaration of response to the death of George Floyd and Black Lives Matter movement—“We stand united in condemning racism, bigotry and discrimination based on race, religion, gender, country of origin and sexual orientation.” Still, there remains an unmet need for a comprehensive and concrete plan of action to overcome these disparities and inequities to bridge the access gap.

The goal is to create provider and institutional-level awareness as well as structural competency to promote true health equity. Therefore, the transplant community must come together to build an infrastructure with accountability within our associations, health systems, and the communities to address SDOH and structural racism. This process begins with critical

self-assessment and training on how physician behaviors and institutional racism directly contribute to inequity in transplantation.

For this policy piece, we focused on the impact of implicit bias and the roles of telemedicine and community outreach, which we believe are critical tools that may reverse the impact of SDOH (Fig. 1). Structural racism, access to affordable insurance, health literacy, and substance abuse therapy are equally important factors that contribute to health disparities and inequities and warrant further commentary and research, but are outside the focus of this policy piece.

## Implicit Bias

Implicit bias, a known social determinant associated with disparities, is defined as attitudes, beliefs, or thoughts beyond the realm of conscious awareness that affect how we view and interact with our environment.<sup>(5,6)</sup> These unconscious beliefs or reactions may affect how we view our patients based on their race/ethnicity, sex identity, or sexual orientation. Data suggest that most health care providers have implicit bias resulting in positive attitudes toward Whites and negative attitudes toward racial/ethnic minorities.<sup>(5)</sup> Furthermore, when assessing for correlations, studies have found a significant positive relationship between implicit bias and lower quality of care.<sup>(6)</sup> As we consider the disparities that exist in access to LT, we must engage in honest conversations as providers about our own implicit biases. As noted above, the transplant evaluation inherently involves multiple subjective assessments that


### ARTICLE INFORMATION:

From the <sup>1</sup>Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY; <sup>2</sup>Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA; <sup>3</sup>Yale New Haven Transplantation Center, New Haven, CT; <sup>4</sup>Division of Transplant and Hepatobiliary Surgery, Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ; <sup>5</sup>Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ; <sup>6</sup>Global Liver Institute, Washington, DC; <sup>7</sup>Division of Gastroenterology and Hepatology, Michigan Medicine, University of Michigan, Ann Arbor, MI; <sup>8</sup>Division of Gastroenterology, Duke School of Medicine, Durham, NC; <sup>9</sup>Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

### ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

Russell Rosenblatt, M.D., M.S.  
Division of Gastroenterology and Hepatology  
Weill Cornell Medicine  
1305 York Avenue, 4th floor

New York, NY 10021  
E-mail: RUR9017@med.cornell.edu  
Tel.: +1-646-962-5483



**FIG. 1.** This figure identifies several targets to chart a course to improving equity in liver transplantation. Key stakeholders are noted and action items are listed. Many other factors are not listed and are crucial to improving equity, but are outside the scope of this paper.

make it particularly sensitive to implicit bias. Therefore, transplant centers must engage in implicit bias training for all transplant team members to promote cultural humility, ultimately leading to a greater understanding and acceptance of how it shapes our overarching narrative around inequities. It will be important to define and call out implicit bias when present and expand upon the understanding of equity from the perspective of marginalized groups. Additionally, given that implicit bias may affect referral patterns of providers for patients of color, limited socioeconomic means, or rural geographical locations, centers need to devise plans to circumnavigate these barriers. Although implicit bias cannot be entirely eliminated, an organizational awareness of its presence and impact on referral patterns and decision making will allow transplant centers to mitigate its contribution to disparities. Emphasis on outreach and community education is particularly important to ensure proper

referral of vulnerable populations with liver disease for transplant evaluation.

## Telemedicine

The COVID-19 pandemic worsened access to care and enhanced inequities among vulnerable populations. However, amid stay-at-home orders and social distancing, health care systems responded quickly by adapting telemedicine to improve access and care while reducing risk of COVID-19 exposure. Consequently, telemedicine has become a burgeoning tool for health care management and may help bridge the transplant access gap for some vulnerable populations, notably those in remote geographical locations.

There is an inherent relationship between access to care and poor outcomes, and limited resources and

distance from a specialist can exacerbate these issues. Yet, telemedicine may address some of these gaps at individual and societal levels. Research on telemedicine adoption has been favorable, while barriers remain, especially for the vulnerable. These include, but are not limited to: (1) low SES (lack of smart devices); (2) limited infrastructure (broadband internet); (3) lack of privacy for virtual visits; (4) older age (inability to use technology); (5) disability (visual or hearing impairment); and (6) language barrier (inability to connect to interpreter services).

Further research on how and when telemedicine should be used is essential to optimize health care delivery to improve health inequities. It is essential to identify the areas where telemedicine would be most impactful in patients with liver disease before and following transplantation. To ensure that telemedicine does not exacerbate disparities, further research is needed to identify barriers to its use as is investigation of alternative means of communication when social distancing is necessary. Therefore, we urge partnerships to develop funding to improve access to telemedicine to ensure equitable access and overcome sociodemographic and -economic disparities.

## Community Engagement

The last component addressed in this policy review is the role of community engagement to overcome SDOH to promote health equity. Those communities most impacted by SDOH are often disproportionately impacted by chronic liver disease and cirrhosis. Community health resources are often lower in Black, Latinx, and American Indian neighborhoods.<sup>(7,8)</sup> Vulnerable neighborhoods have high rates of obesity and NAFLD (exacerbated by food deserts), alcohol use disorder (increased environmental stress without appropriate substance abuse and mental health resources), and hepatitis C (with less access to direct-acting antivirals).<sup>(9)</sup> COVID-19 has disproportionately impacted these same communities—notably, Blacks with chronic liver disease.<sup>(10)</sup>

Therefore, it is crucial to identify and empower partners through community engagement for education and creation of referral networks to serve patients with liver disease. This engagement will foster the creation of partnerships focused on health equity that can respond to a variety of liver health-limiting factors.

Additionally, health systems need to prioritize cirrhosis care in communities with higher burden of liver disease. Efforts to overcome SDOH-related limited access to effective treatments are necessary. Whereas chronic liver disease requiring transplant is more common in vulnerable patient populations, early identification and education can reduce morbidity and mortality. Working with community advocates and developing partnerships to meet these goals are equally important for providers, individual centers, and large organizations.

## Conclusion

Although inequity in chronic liver disease and transplantation has been longstanding, there are many SDOHs that can be targeted to bridge the gap. Acknowledging and training to overcome implicit bias is crucial for all health care providers. Telemedicine offers a new technology to reach patients who were previously unreachable, yet there are issues with implementation, the potential to exacerbate disparities, and need for research to validate its effectiveness in LT evaluations. Finally, the AASLD, centers, and practitioners must continue to engage and work with patient advocates and community groups to improve access. These tools provide a framework to build both personal and structural competency to ensure that all patients, regardless of SDOH, have equitable access to care and transplant.

*Acknowledgment:* The authors would like to acknowledge Tamar Taddei, Jorge Bezerra, and Matthew D'Uva for their assistance in organizing this group and reviewing the content.

*Author Contributions:* Substantial contributions to conception and design: R.R., H.L., A.L., K.E.L., A.S., P.S., J.W. Drafting the article or revising it critically for important intellectual content: R.R., H.L., A.L., K.E.L., A.S., P.S., J.W. Final approval: R.R., H.L., A.L., K.E.L., A.S., P.S., J.W.

## REFERENCES

- 1) Kardashian A, Wilder J, Terrault NA, Price JC. Addressing social determinants of liver disease during the COVID-19 pandemic and beyond: a call to action. *HEPATOLOGY* 2021;73:811-820.
- 2) Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, U.S. Department of Health and Human Services. Social determinants of health. <https://health.gov/healthypeople/objectives-and-data/social-determinants-health>. Accessed March 5, 2021.

- 3) Wahid N, Rosenblatt R, Brown RSJ. A review of the current state of liver transplantation disparities. *Liver Transplant* 2021;27:434-443.
- 4) Bittermann T, Dwinnells K, Chadha S, Wolf MS, Olthoff KM, Serper M. Low health literacy is associated with frailty and reduced likelihood of liver transplant listing: a prospective cohort study. *Liver Transplant* 2020;26:1409-1421.
- 5) Hall WJ, Chapman MV, Lee KM, Merino YM, Thomas TW, Payne BK, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. *Am J Public Health* 2015;105:e60-e76.
- 6) Fitzgerald C, Hurst S. Implicit bias in healthcare professionals: a systematic review. *BMC Med Ethics* 2017;18:19.
- 7) DiMaggio C, Klein M, Berry C, Frangos S. Black/African American communities are at highest risk of COVID-19: spatial modeling of New York City ZIP Code-level testing results. *Ann Epidemiol* 2020;51:7-13.
- 8) Warne D, Lajimodiere D. American Indian health disparities: psychosocial influences. *Soc Personal Psychol Compass* 2015;9:567-579.
- 9) Marcus JL, Hurley LB, Chamberland S, Champisi JH, Gittleman LC, Korn DG, et al. Disparities in initiation of direct-acting antiviral agents for hepatitis C virus infection in an insured population. *Public Health Rep* 2018;133:452-460.
- 10) Wang Q, Davis PB, Xu R. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. *EClinicalMedicine* 2021;31:100688.